Fate Therapeutics, Inc. (FATE)

NASDAQ: FATE · IEX Real-Time Price · USD
4.365
+0.095 (2.22%)
Jul 22, 2024, 12:23 PM EDT - Market open
2.22%
Market Cap 480.37M
Revenue (ttm) 6.48M
Net Income (ttm) -190.05M
Shares Out 113.83M
EPS (ttm) -1.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 371,267
Open 4.330
Previous Close 4.270
Day's Range 4.164 - 4.470
52-Week Range 1.630 - 8.830
Beta 1.90
Analysts Buy
Price Target 6.85 (+56.93%)
Earnings Date Aug 6, 2024

About FATE

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company’s chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 1, 2013
Employees 181
Stock Exchange NASDAQ
Ticker Symbol FATE
Full Company Profile

Financial Performance

In 2023, FATE's revenue was $63.53 million, a decrease of -34.03% compared to the previous year's $96.30 million. Losses were -$160.93 million, -42.88% less than in 2022.

Financial Statements

Analyst Forecast

According to 15 analysts, the average rating for FATE stock is "Buy." The 12-month stock price forecast is $6.85, which is an increase of 56.93% from the latest price.

Price Target
$6.85
(56.93% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, July 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent s...

19 days ago - GlobeNewsWire

FATE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Fate Therapeutics, Inc. (NASDAQ: FATE) and Encourages Long-Term FATE Investors to Contact the Firm

PHILADELPHIA , June 13, 2024 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Fate Therapeutics, Inc. (NASDAQ: FATE) ("Fate") on behalf of the company's long-term investors. Recently...

5 weeks ago - PRNewsWire

Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference

SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-c...

7 weeks ago - GlobeNewsWire

Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

First Lupus Patient Treated with FT819 CAR T-cell Product Candidate in Phase 1 Autoimmunity Study; Future Clinical Development of FT819 to Focus Exclusively on Autoimmune Disease

2 months ago - GlobeNewsWire

Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program

Pre-treatment Sample of Patient's Blood Showed Rapid and Potent Depletion of CD19+ B Cells in Ex Vivo Cytotoxicity Assay with FT819

2 months ago - GlobeNewsWire

Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting

Off-the-shelf, CD19-targeted CAR NK Cell Product Candidate Drives Rapid and Deep Depletion of SLE Donor CD19+ B cells

2 months ago - GlobeNewsWire

Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting

Key Therapeutic Mechanisms of Clinical Activity for Autoimmune Diseases, including B cell Depletion, Tissue Infiltration and Immune Reconstitution Data, from Phase 1 Study of FT819 in Relapsed / Refra...

3 months ago - GlobeNewsWire

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, April 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent ...

3 months ago - GlobeNewsWire

Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement

SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in...

4 months ago - GlobeNewsWire

Fate Therapeutics to Present at Upcoming March Investor Conferences

SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in...

5 months ago - GlobeNewsWire

Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

CIRM Grant Awarded to Support Phase 1 Autoimmunity Study of FT819 CD19-targeted CAR T-cell Program for Systemic Lupus Erythematosus; Study Start-up Ongoing at Multiple Clinical Sites

5 months ago - GlobeNewsWire

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results

SAN DIEGO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-...

5 months ago - GlobeNewsWire

Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent s...

7 months ago - GlobeNewsWire

Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Phase 1 Study Open for Enrollment of FT522 ADR-armed, CD19-targeted CAR NK Cell Program for B-cell Lymphoma; Dose Escalation Designed to Assess 3-dose Treatment Schedule with and without Conditioning ...

9 months ago - GlobeNewsWire

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results

SAN DIEGO, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-...

9 months ago - GlobeNewsWire

Fate Therapeutics to Present at Upcoming September Investor Conferences

SAN DIEGO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-...

11 months ago - GlobeNewsWire

Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates

Phase 1 Study Start-up Ongoing for FT522 ADR-armed, CD19-targeted CAR NK Cell Program for B-cell Lymphoma; Dose Escalation Designed to Assess 3-dose Treatment Schedule with and without Conditioning Ch...

1 year ago - GlobeNewsWire

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results

SAN DIEGO, July 28, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-...

1 year ago - GlobeNewsWire

FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fate Therapeutics, Inc. (NASDAQ: FATE) ...

1 year ago - Business Wire

Fate ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fate Therapeutics, Inc. (NASDAQ: FATE) on be...

1 year ago - Business Wire

Fate Therapeutics to Present at Upcoming June Investor Conferences

SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-c...

1 year ago - GlobeNewsWire

Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates

Dose Escalation Ongoing in Landmark Phase 1 Study of FT819 CD19-targeted 1XX CAR T-cell Program; Interim Clinical Data Demonstrated Favorable Safety Profile and Complete Responses in Aggressive Large ...

1 year ago - GlobeNewsWire

Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2023 Financial Results

SAN DIEGO, April 24, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in...

1 year ago - GlobeNewsWire

FINAL DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important March 22 Deadline in Securities Class Action – FATE

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fate Therapeutics, Inc. (NASDAQ: FATE) between April 2, 2020 and January 5, 2...

1 year ago - Business Wire

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Fate Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 22, 2023 - (NASDAQ: FATE)

NEW YORK , March 22, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Fate Therapeutics, Inc.. Shareholders who purchased shares of FATE during the class period l...

1 year ago - PRNewsWire